Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Get in touch with Ying-hui
Contact Ying-hui, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck RackActions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Articles
The Pharmacokinetics, Pharmacodynamics, Tolerability, and Safety of Orally Dosed QY201, a Novel JAK1/TYK2 Inhibitor, in Chinese Healthy Subjects
Conflicts of Interest All authors declare no competing interests. Supporting Information Filename Description jcph70053-sup-0001-SuppMat.docx12.9 MB Supporting Information References 1, , , , , . JAK inhibition as a therapeutic strategy for immune and inflammatory diseases. Nat Rev Drug Discov. 2017; 16(12): 843-862. 2, , , . The regulation of JAKs in cytokine signaling and its breakdown in disease. Cytokine. 2019; 118: 48-63. 3, , , et al.
SHAP Analysis of Machine Learning-based Carotid Atherosclerosis predic
Back to Journals » Nature and Science of Sleep » Volume 17 Authors Cai WM , Rui D, Zhao LB, Gao YH, Zhao Z, Xue X, Li TJ, Nie TY, Ma Y , Liu L Received 10 November 2024 Accepted for publication 27 July 2025 Published 29 September 2025 Volume 2025:17 Pages 2351—2367 DOI https://doi.org/10.2147/NSS.S505241 Checked for plagiarism Yes Review by Single anonymous peer review Peer reviewer comments 4 Editor who approved publication: Prof.
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with Ying-hui
Contact Ying-hui, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack